COVID-19 and Clinical Trials: a CRO's…
OCT to Remain Fully Operational, Available…
Leading mid-size European CRO approved to begin work on bioequivalence study; seeks marketing authorization for all member states of EAEU.
ST. PETERSBURG, RUSSIA — March 19, 2020. OCT Clinical, a leading European CRO headquartered in Russia, today announced it has successfully obtained a clinical trial approval to conduct a bioequivalence study on behalf of a European pharmaceutical company.
The open-label, randomized, single-dose, two-treatment, two-sequence, two-way crossover, pivotal bioequivalence study will test an investigational drug: a film-coated tablet composed of a combination of rosuvastatin and ezetimibe. The primary objective of the study is to evaluate comparative pharmacokinetics and bioequivalence under fasting conditions.
110 healthy volunteers are to be screened, and 88 of them will be randomized within a specialized Phase I unit in Russia. The planned duration of the study is six months, with the ultimate goal to obtain a marketing authorization valid within all the member states of the Eurasian Economic Union (EAEU).
“We see growing interest among sponsors from all over the world for their drugs to have marketing authorization across the entire Eurasian Economic Union while having registered them in only one of the member countries,” said Irina Petrova, Director of Medical Operations, OCT Clinical. “We are positive that our experience will allow us to meet all the Sponsor's goals. We are very excited about this project and we are committed to delivering excellence during every stage of the study.”
Within this project, the OCT Clinical team is responsible for a wide scope of clinical trial services: project management, pharmacovigilance and medical monitoring, data management and biostatistics, medical writing, logistics support, and regulatory support, including CSR submission to regulatory authorities.
“We have high expectations for the outcome of this project through our collaboration with OCT Clinical,” said a representative from the study Sponsor. “Throughout our experience of working with OCT they have demonstrated a consistent level of competence, thus matching our highest aspirations by keeping timelines, delivering effective communication on a 24/7 basis, and providing continuous assistance.”